Ads
related to: Sage Onedatasnipper.com has been visited by 10K+ users in the past month
bark.com has been visited by 100K+ users in the past month
Search results
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Zacks via Yahoo Finance· 10 hours agoData from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a...
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Zacks via Yahoo Finance· 8 hours agoAdditionally, feedback from...depressive episodes associated with bipolar I or II disorder in adults...
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Investor's Business Daily· 1 day agoSage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study. Sage stock...
Sages baseball remains undefeated, Glenwood soccer's offense flourishes against Rochester
FOX Illinois· 15 hours agoMonticello baseball entered Wednesday undefeated and 20-0 on the season, looking to improve on their...
Sage Growth Partners Expands Account Leadership Team
WPRI Providence· 13 hours agoSage Growth Partners (SGP), a Baltimore-based healthcare research, strategy, and marketing firm, is pleased to announce the hiring of Michelle McNickle as an Account Group ...
Sage Therapeutics stock plunges 23 percent after Parkinson’s drug fails study - The Boston Globe
The Boston Globe· 1 day agoShares of Sage Therapeutics hit a record low Wednesday after the Cambridge biotech announced that...
Sage Therapeutics (NASDAQ:SAGE) Downgraded to “Underperform” at Bank of America
ETF DAILY NEWS· 18 hours agoBank of America downgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) from a neutral rating to an underperform rating in a research note released ...
Sage halts trials in Parkinson’s after drug fails to show benefit - Boston Business Journal
The Business Journals· 1 day agoSage Therapeutics Inc. has decided to halt work on an experimental drugs in Parkinson’s disease...
Sage Therapeutics stock maintains neutral rating, price target at $20 By Investing.com
Investing.com· 1 day agoOn Wednesday, Mizuho maintained its Neutral stance on Sage Therapeutics (NASDAQ:SAGE) with a...
Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Wedbush
ETF DAILY NEWS· 19 hours agoWedbush reiterated their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report issued on Wednesday morning, Benzinga reports ...